Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Stratec

BATS-CHIXE:SBSD
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SBSD
BATS-CHIXE
€962M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Stratec has significant price volatility in the past 3 months.
SBSD Share Price and Events
7 Day Returns
15.4%
BATS-CHIXE:SBSD
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
22.3%
BATS-CHIXE:SBSD
-0.3%
GB Medical Equipment
-23.6%
GB Market
SBSD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Stratec (SBSD) 15.4% 23.2% 27.7% 22.3% 44.2% -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • SBSD outperformed the Medical Equipment industry which returned -0.3% over the past year.
  • SBSD outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
SBSD
Industry
5yr Volatility vs Market

Value

 Is Stratec undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Stratec to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Stratec.

BATS-CHIXE:SBSD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.5%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:SBSD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 30%) (9.69%))
0.908
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.91
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.908 * 5.44%)
5.47%

Discounted Cash Flow Calculation for BATS-CHIXE:SBSD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Stratec is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:SBSD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5.47%)
2020 17.00 Analyst x1 16.12
2021 33.80 Analyst x2 30.39
2022 34.00 Analyst x1 28.98
2023 34.18 Est @ 0.54% 27.63
2024 34.37 Est @ 0.54% 26.33
2025 34.55 Est @ 0.53% 25.10
2026 34.73 Est @ 0.53% 23.93
2027 34.92 Est @ 0.53% 22.81
2028 35.11 Est @ 0.53% 21.74
2029 35.29 Est @ 0.53% 20.72
Present value of next 10 years cash flows €243.00
BATS-CHIXE:SBSD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €35.29 × (1 + 0.53%) ÷ (5.47% – 0.53%)
€718.37
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €718.37 ÷ (1 + 5.47%)10
€421.80
BATS-CHIXE:SBSD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €243.00 + €421.80
€664.80
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €664.80 / 12.03
€55.28
BATS-CHIXE:SBSD Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:SBSD represents 0.97987x of XTRA:SBS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.97987x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 55.28 x 0.97987
€54.17
Value per share (EUR) From above. €54.17
Current discount Discount to share price of €80.35
= -1 x (€80.35 - €54.17) / €54.17
-48.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Stratec is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Stratec's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Stratec's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:SBSD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €1.34
XTRA:SBS Share Price ** XTRA (2020-04-06) in EUR €82
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Stratec.

BATS-CHIXE:SBSD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:SBS Share Price ÷ EPS (both in EUR)

= 82 ÷ 1.34

61.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stratec is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Stratec is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Stratec's expected growth come at a high price?
Raw Data
BATS-CHIXE:SBSD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 61.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
21%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:SBSD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 61.12x ÷ 21%

2.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stratec is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Stratec's assets?
Raw Data
BATS-CHIXE:SBSD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €13.22
XTRA:SBS Share Price * XTRA (2020-04-06) in EUR €82
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:SBSD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:SBS Share Price ÷ Book Value per Share (both in EUR)

= 82 ÷ 13.22

6.2x

* Primary Listing of Stratec.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stratec is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Stratec's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Stratec has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Stratec expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Stratec expected to grow at an attractive rate?
  • Stratec's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Stratec's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Stratec's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:SBSD Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:SBSD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 21%
BATS-CHIXE:SBSD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 9.5%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:SBSD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:SBSD Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 361 74 51 3
2023-12-31 334 66 44 3
2022-12-31 305 55 39 3
2021-12-31 278 49 32 4
2020-12-31 251 43 23 4
2020-04-07
BATS-CHIXE:SBSD Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 222 21 16
2019-09-30 214 8 14
2019-06-30 209 13 14
2019-03-31 196 9 11
2018-12-31 188 12 11
2018-09-30 193 20 16
2018-06-30 197 28 23
2018-03-31 198 28 24
2017-12-31 207 30 27
2017-09-30 208 30 28
2017-06-30 206 21 20
2017-03-31 203 19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Stratec's earnings are expected to grow significantly at over 20% yearly.
  • Stratec's revenue is expected to grow by 9.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:SBSD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Stratec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:SBSD Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 4.22 4.22 4.22 1.00
2023-12-31 3.66 3.66 3.66 1.00
2022-12-31 2.97 3.12 2.82 2.00
2021-12-31 2.73 3.28 2.39 3.00
2020-12-31 1.90 2.02 1.79 2.00
2020-04-07
BATS-CHIXE:SBSD Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 1.34
2019-09-30 1.13
2019-06-30 1.15
2019-03-31 0.96
2018-12-31 0.93
2018-09-30 1.38
2018-06-30 1.92
2018-03-31 2.03
2017-12-31 2.24
2017-09-30 2.35
2017-06-30 1.66
2017-03-31 1.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Stratec is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Stratec's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Stratec has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Stratec performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Stratec's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Stratec's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Stratec's 1-year earnings growth exceeds its 5-year average (44.8% vs -6.7%)
  • Stratec's earnings growth has exceeded the GB Medical Equipment industry average in the past year (44.8% vs -9.5%).
Earnings and Revenue History
Stratec's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Stratec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:SBSD Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 221.64 16.09 27.46 5.11
2019-09-30 214.25 13.53 31.86 8.80
2019-06-30 209.26 13.79 31.24 8.61
2019-03-31 195.85 11.47 31.24 9.23
2018-12-31 187.82 11.11 23.92 10.06
2018-09-30 192.69 16.42 26.28 8.73
2018-06-30 196.95 22.85 25.95 9.73
2018-03-31 197.61 24.20 26.88 9.90
2017-12-31 207.48 26.59 30.63 9.90
2017-09-30 208.00 27.92 32.41 7.92
2017-06-30 206.34 19.69 33.17 7.57
2017-03-31 203.20 19.49 34.47 7.89
2016-12-31 184.91 19.50 28.83 8.05
2016-09-30 166.02 14.05 25.52 9.65
2016-06-30 154.91 18.68 22.49 10.10
2016-03-31 143.56 20.77 17.87 8.84
2015-12-31 146.89 22.08 18.40 8.34
2015-09-30 146.78 21.53 17.86 5.11
2015-06-30 145.82 20.65 16.88 5.43
2015-03-31 145.04 20.85 16.42 5.17
2014-12-31 144.86 19.77 17.11 5.02
2014-09-30 142.41 19.46 15.72 7.33
2014-06-30 136.93 17.86 15.83 5.98
2014-03-31 132.04 15.52 16.62 5.18
2013-12-31 127.95 15.48 15.96 5.05
2013-09-30 125.90 11.76 17.09 4.87
2013-06-30 124.50 11.64 17.59 4.22

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Stratec has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Stratec used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Stratec's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Stratec's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Stratec has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Stratec's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Stratec's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Stratec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Stratec's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Stratec's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Stratec Company Filings, last reported 3 months ago.

BATS-CHIXE:SBSD Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 159.01 84.53 24.03
2019-09-30 150.98 89.09 17.34
2019-06-30 148.57 75.18 21.53
2019-03-31 153.23 74.85 25.98
2018-12-31 152.20 69.53 24.64
2018-09-30 147.37 59.98 26.58
2018-06-30 142.58 60.38 28.22
2018-03-31 155.48 60.48 40.44
2017-12-31 157.84 62.51 36.64
2017-09-30 148.51 69.77 31.73
2017-06-30 141.08 68.56 23.44
2017-03-31 147.91 69.35 35.47
2016-12-31 142.34 71.51 32.20
2016-09-30 131.92 3.91 29.78
2016-06-30 129.19 0.00 27.44
2016-03-31 130.28 5.11 57.89
2015-12-31 130.28 5.11 57.89
2015-09-30 123.74 5.26 55.65
2015-06-30 118.03 6.05 50.06
2015-03-31 120.44 8.52 59.51
2014-12-31 112.05 0.00 46.94
2014-09-30 106.09 7.11 35.32
2014-06-30 100.17 7.81 27.87
2014-03-31 101.11 7.86 28.32
2013-12-31 97.18 8.74 21.38
2013-09-30 95.87 8.68 19.24
2013-06-30 92.13 8.31 14.49
  • Stratec's level of debt (53.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.1% vs 53.2% today).
  • Debt is well covered by operating cash flow (25.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 21x coverage).
X
Financial health checks
We assess Stratec's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Stratec has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Stratec's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.02%
Current annual income from Stratec dividends. Estimated to be 1.47% next year.
If you bought €2,000 of Stratec shares you are expected to receive €20 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Stratec's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Stratec's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Upcoming dividend payment

Purchase Stratec before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:SBSD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:SBSD Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31 1.71 2.00
2023-12-31 1.51 2.00
2022-12-31 1.18 3.00
2021-12-31 1.01 4.00
2020-12-31 0.84 2.00
2020-04-07
BATS-CHIXE:SBSD Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-04-02 0.840 1.063
2019-05-29 0.820 1.278
2018-04-19 0.800 1.284
2017-06-14 0.770 1.250
2016-06-09 0.750 1.462
2015-05-22 0.700 1.401
2014-06-18 0.600 1.391
2013-04-18 0.500 1.546
2012-07-24 0.550 1.567
2012-03-12 0.550 1.686
2011-02-22 0.500 1.683
2010-03-01 0.450 1.570

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stratec is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • Stratec is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Stratec's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Stratec's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.9x coverage).
X
Income/ dividend checks
We assess Stratec's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Stratec afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Stratec has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Stratec's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marcus Wolfinger
COMPENSATION €1,064,000
AGE 52
TENURE AS CEO 9 years
CEO Bio

Mr. Marcus Wolfinger has been Chairman of Management Board and Chief Executive Officer at STRATEC Biomedical AG since April 01, 2011 and its Member of the Management Board since July 1999. Mr. Wolfinger has been employed at STRATEC Biomedical AG since February 1998. He served as the Chief Financial Officer of STRATEC Biomedical AG. He served at leading companies in the IT and consumer goods industries. He served as Member of Supervisory Board of CyBio AG since October 2006. Mr. Wolfinger graduated in Business Administration.

CEO Compensation
  • Marcus's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Marcus's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Stratec management team in years:

9
Average Tenure
52
Average Age
  • The average tenure for the Stratec management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Marcus Wolfinger

TITLE
Chairman of Board of Management & CEO
COMPENSATION
€1M
AGE
52
TENURE
9 yrs

Robert Siegle

TITLE
Director of Finance & Human Resources and Member of Board of Management
COMPENSATION
€765K
AGE
52
TENURE
9.2 yrs

Claus Vielsack

TITLE
Director of Product Development & Member of Board of Management
COMPENSATION
€669K
AGE
52
TENURE
6.2 yrs

Hermann Leistner

TITLE
Founder & Advisor
AGE
73
TENURE
9.1 yrs

Sandra Eberle

TITLE
Head of Investor Relations

Andre Loy

TITLE
Director of Corporate Communications

Roland Utz

TITLE
Head of Supply Chain Management & Senior VP
Board of Directors Tenure

Average tenure and age of the Stratec board of directors in years:

2.8
Average Tenure
53
Average Age
  • The average tenure for the Stratec board of directors is less than 3 years, this suggests a new board.
Board of Directors

Frank Hiller

TITLE
Chairman of the Supervisory Board
AGE
53
TENURE
0.9 yrs

Rainer Baule

TITLE
Deputy Chairman of Supervisory Board
COMPENSATION
€41K
AGE
71
TENURE
2.8 yrs

Stefanie Remmele

TITLE
Member of Supervisory Board
COMPENSATION
€29K
AGE
41
TENURE
5.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Stratec's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Stratec has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates in three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technology. STRATEC SE also develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to STRATEC SE in December 2018. STRATEC SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

Details
Name: Stratec SE
SBSD
Exchange: BATS-CHIXE
Founded: 1979
€962,024,000
12,025,300
Website: http://www.stratec.com
Address: Stratec SE
Gewerbestrasse 35-37,
Birkenfeld,
75217,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA SBS Registered Shares XETRA Trading Platform DE EUR 05. Oct 1998
DB SBS Registered Shares Deutsche Boerse AG DE EUR 05. Oct 1998
LSE 0RAR Registered Shares London Stock Exchange GB EUR 05. Oct 1998
SWX SBS Registered Shares SIX Swiss Exchange CH CHF 05. Oct 1998
BATS-CHIXE SBSD Registered Shares BATS 'Chi-X Europe' GB EUR 05. Oct 1998
ETLX SBS Registered Shares Eurotlx IT EUR 05. Oct 1998
Number of employees
Current staff
Staff numbers
1,223
Stratec employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 19:46
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/04/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.